Novelion Therapeutics names executive chair, interim CEO
Insight Weekly: Sustainable bonds face hurdles; bad loans among landlords; AI investments up
Insight Weekly: Bank oversight steps up; auto insurers’ dismal year; VC investment slumps
Insight Weekly: Renewables lead capacity additions; bank mergers of equals up; nickel IPOs surge
Insight Weekly: Utilities face headwinds; S&P 500 dividend hikes likely; dollar poised for rally
Canada's Novelion Therapeutics Inc. appointed Mark Corrigan to serve as executive chair of the board.
Further, COO Jeff Hackman was named interim CEO.
The company said in relation to Corrigan's appointment, the office of the CEO — comprising Corrigan, Hackman and former Chair Jason Aryeh — will be disbanded.
Novelion develops therapies for individuals with rare diseases.
